Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesotherapy for Irritable Bowel Syndrome
NCT06261320Phase 2Active, not recruiting
- Sponsor
- Polyclinique de l'Europe
- Start
- Feb 2024
- Primary completion
- Dec 2026
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trimecaine, thiocolchicoside, amitriptyline and Pidolic acid in irritable bowel syndrome (IBS), sponsored by Polyclinique de l'Europe. Primary endpoint: Irritable Bowel Syndrome Symptom Severity Scale at day 45. Started Feb 2024; status: active, not recruiting.
02
Drugs
trimecainethiocolchicosideamitriptylinePidolic acid
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT06261320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06261320.